WilliamAFloodMDMSc

Oncology • Philadelphia, PA

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Chief Medical Officer, eviti

Join to view full profile

Dr. Flood is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Flood's full profile

Already have an account?

Office
1800 JFK Blvd
9th Floor
Philadelphia, PA 19103
Phone+1 866-968-7482
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1996
Duke University HospitalResidency, Internal Medicine, 1990 - 1993
Lewis Katz School of Medicine at Temple UniversityClass of 1990

Certifications & Licensure

PA State Medical License 1997 - 2024
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

629 citations
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncolo...
Barbara Burtness, Meredith A. Goldwasser, William A. Flood, Bassam Mattar, Arlene A. Forastiere> ;Journal of Clinical Oncology. 2005 Dec 1
11 citations
Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin.
W Flood, Ding-Jen Lee, A Trotti, Sharon A. Spencer, Barbara A. Murphy, Fadlo R. Khuri, Ronald C. DeConti, R Wheeler, Arlene A. Forastiere> ;Seminars in Radiation Oncology. 1999 Apr 1
6 citations
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
E K Rowinsky, W A Flood, S E Sartorius, K M Bowling, D S Ettinger> ;Investigational New Drugs. 1997 Jan 1
Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
E K Rowinsky, W A Flood, S E Sartorius, M K Bowling, J Wagner, D S Ettinger> ;Seminars in Oncology. 1995 Aug 1
Join now to see all

Press Mentions

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer CareDecember 9th, 2020
NantHealth’s Cancer Therapy Pre-Authorization Platform Eviti Connect® Starts 2020 Strong with Two Expanded ProgramsFebruary 27th, 2020
Improving Member Cancer Care and Your Bottom LineSeptember 10th, 2018